# Therypharm Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therypharm-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.therypharm.com
- Total disclosed funding: $37M
- Latest round: Series C (Sep 24, 2020)
- Investors on record: 7

## About

Established in 2010 and based in Suzhou, China, Therypharm Pharmaceutical Co., Ltd is a pharmaceutical formulation manufacturing company specializing in the development, production and sale of specialty APIs and high-end formulations. The company has 4 wholly-owned or holding subsidiaries, a 4,000 square meter R&D center and pilot base, a 1,300 square meter cGMP formulation production base, and a 12,000 square meter cGMP API production base in Suzhou Hi-Tech Zone.

The company mainly produces aseptic injections and oral solid dosage forms, covering oncology drugs, digestive system drugs, cardiovascular and cerebral vascular drugs, etc., and also carries out the technological development of drugs and drug intermediates.

## Funding rounds

- Series C, Sep 24, 2020, $37M — Legend Capital, GP Capital, SND Ventures Group, Suzhou International Development Venture Capital Holding, CEC Capital, Honest Capital
- Series B, Jan 1, 2018 — Legend Capital, Tenyall & Sumin

## Investors

- Legend Capital — Series B, Series C
- Tenyall & Sumin — Series B
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series C
- SND Ventures Group (https://capitalatlas.ai/funds/snd-ventures-group) — Series C
- Suzhou International Development Venture Capital Holding (https://capitalatlas.ai/funds/suzhou-international-development-venture-capital-holding) — Series C
- CEC Capital (https://capitalatlas.ai/funds/cec-capital) — Series C
- Honest Capital (https://capitalatlas.ai/funds/honest-capital) — Series C